AMACR Detection in Prostate Secretions for Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing prostate cancer are non-specific and invasive, with PSA tests having low specificity and biopsies being costly and painful, while missing significant cancers or resulting in false negatives, and there is a need for a more accurate and non-invasive method.
Innovation Solution
A method and kit for detecting alpha methylacyl A coenzyme racemase (AMACR) in semen or prostate secretions using antibodies and immunoassays, such as ELISA, to diagnose prostate cancer or precancerous conditions by determining AMACR levels above a minimum threshold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PSA test is used for prostate cancer screening, then the test can be performed non-invasively, but the specificity is low (30%) and it cannot diagnose prostate cancer accurately
Solution Approach 1:
The patent uses AMACR as an intermediary biomarker that specifically targets prostate cancer cells. Instead of relying on PSA which is produced by both benign and malignant prostate tissue, the invention detects AMACR which is overexpressed specifically in prostate cancer cells, thereby achieving both non-invasive testing and high specificity
Solution Approach 2:
The patent changes the detection parameter from PSA levels to AMACR expression levels. By measuring the ratio of AMACR to PSA or detecting AMACR alone in prostate fluid, the test achieves superior specificity while maintaining the non-invasive nature of the original PSA test
2Ease of operation
If digital rectal examination is used, then the test is simple to perform, but it can only detect abnormalities in the back wall of the prostate and cannot diagnose cancer
Solution Approach 1:
The patent introduces AMACR as a molecular intermediary that can be detected in prostate fluid obtained through minimally invasive methods. This allows detection of cancer-specific biomarkers throughout the entire prostate gland, not just the back wall accessible to digital rectal examination
3Measurement precision
If prostate needle biopsy is performed, then the diagnosis accuracy is high, but the procedure is costly, painful, and can miss significant cancers or give false-negative results
Solution Approach 1:
The patent performs preliminary detection of AMACR in prostate fluid before conducting a biopsy. This preliminary action identifies patients who are most likely to have prostate cancer, allowing clinicians to target biopsies more precisely and reduce the number of unnecessary biopsies, thereby reducing pain and complications while maintaining high diagnosis accuracy
Solution Approach 2:
The patent uses AMACR detection results as feedback to guide biopsy decisions. By measuring AMACR levels in prostate fluid and using this information to determine which areas to biopsy or whether to biopsy at all, the system optimizes diagnostic accuracy while minimizing harmful effects of unnecessary biopsies
4Measurement precision
If repeat biopsies are performed on patients with persistently elevated PSA, then the chance of diagnosis increases, but the cost, pain, and anxiety increase while many patients still receive false-negative results
Solution Approach 1:
The patent uses AMACR as a more specific intermediary biomarker to replace repeated PSA testing. Since AMACR is specifically overexpressed in prostate cancer cells rather than benign tissue, a single AMACR test can provide more reliable diagnostic information, reducing the need for repeated testing and the associated time loss and patient anxiety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a non-invasive and specific test for detecting prostate cancer, potentially replacing current PSA tests, with higher accuracy and reducing the need for invasive biopsies, by quantifying AMACR levels in semen or prostate secretions.
Implementation Method 1
The fluid is contacted with a reagent for detecting AMACR under conditions such that the reagent detects AMACR in the semen
Data Source
AI summary
A method of detecting the presence or absence of alpha methylacyl A coenzyme racemase (AMACR) is provided. In one embodiment of the method, a fluid including a secretion chosen from at least one of a prostate secretion or a secretion from an accessory glad or a cellular component of the fluid is obtained from a subject. The fluid is contacted with a reagent for detecting AMACR under conditions such that the reagent detects AMACR in the semen. The level of AMACR is determined such as by comparing it to a standard curve. The fluid can be semen or a prostate secretion or another fluid. A kit that can be used with the method is also provided.